CollPlant Biotechnologies (CLGN) Equity Average (2019 - 2025)

CollPlant Biotechnologies' Equity Average history spans 7 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Equity Average fell 53.24% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, down 53.24%, while the annual FY2025 figure was $9.8 million, 53.24% down from the prior year.
  • Equity Average reached $9.8 million in Q4 2025 per CLGN's latest filing, down from $20.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $38.7 million in Q4 2022 to a low of $9.8 million in Q4 2025.
  • Average Equity Average over 5 years is $24.9 million, with a median of $24.8 million recorded in 2021.
  • Peak YoY movement for Equity Average: skyrocketed 479.08% in 2021, then tumbled 53.24% in 2025.
  • A 5-year view of Equity Average shows it stood at $24.8 million in 2021, then skyrocketed by 56.06% to $38.7 million in 2022, then decreased by 21.68% to $30.3 million in 2023, then crashed by 31.04% to $20.9 million in 2024, then crashed by 53.24% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for CLGN's Equity Average are $9.8 million (Q4 2025), $20.9 million (Q4 2024), and $30.3 million (Q4 2023).